Tuesday, July 10, 2012

Should China & Taiwan work closer together in clinical trials?

Late last month, Chi-Huey Wong, president of Academia Sin, discussed the importance of China and Taiwan working together to better conduct clinical trials. "Promoting clinical trials under the terms of the agreement is an issue that cannot be delayed." In December 2010, they signed the Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs according to Focus Taiwan.  With the Medical industry booming in Asia, it is expected to account for close to 33% of the market in the coming years.  By integrating the Chinese and Taiwanese systems, they'd be able to take advantage of the strong clinical strengths of both countries.

This fall in Shanghai at Partnerships in Clinical Trials Asia, Melvin Toh, Vice President Pharmaceutical Development, CK Life Science, Bradley Marchant, Senior Director, Asia Pacific R&D, Sanofi Aventis, Danny Soon, Managing Director & Principal Investigator, Lilly-NUS Centre for Clinical Pharmacology will be on hand to discuss what role countries scuh as Taiwan can have in clinical development in the presentation, "Singapore, Hong Kong, Taiwan, Korea: What Role Do Highly Developed Territories Play in Clinical Development?". For more information on this session and the rest of the program, download the agenda. If you'd like to join us in Shanghai this September 12-14, when you register today and mention code XP1775BLOG, you'll save 15% off the standard rate!

What benefits can collaboration between Taiwan and China have for the clinical trials industry?

No comments: